Ibogaine
Viewing r1 — Apr 26, 2026 — CURRENT
Back to HistoryInteractions, related substances, and reports reflect the current entry and are not shown for historical revisions.
Ibogaine is a naturally-occurring psychedelic of the iboga alkaloid class. It comes from the root bark of Tabernanthe iboga, used in Central African spiritual traditions for centuries. It acts on opioid, serotonin, and glutamate brain systems simultaneously, producing its unusual anti-addictive effects.[1][2][3]
Psychedex is in open beta. We are still fine-tuning the generation and review process. Please double-check sources.
Ibogaine was first isolated in 1901, but the Bwiti people of Central Africa used iboga root bark in spiritual ceremonies long before. Howard Lotsof discovered its anti-addictive potential in 1962; the US classified it Schedule I in 1970, and clinical development stalled. A 2024 trial in veterans showed large PTSD benefits,[4] and a 2026 executive order is now accelerating US regulatory review.
Subjective effects include waking visions of personal memories, emotional catharsis, panoramic autobiographical recall, and a detached observer-like perspective on one's own life. The experience is unlike any classical psychedelic — rather than distorting the outside world, ibogaine generates an internal dream-cinema of personal memories. Severe loss of coordination, persistent nausea, and complete sleep suppression are unavoidable physical effects.
Ibogaine does not cause physical dependence,[5] but it can trigger fatal heart arrhythmia at therapeutic doses by blocking a cardiac electrical channel.[6] This risk extends for days after ingestion because the metabolite noribogaine clears slowly; opioids, heart medications, and common antidepressants amplify it significantly. Clinical evidence is building but rests on open-label studies — no large placebo-controlled trial has been completed.
History[edit]
Discovery
Ibogaine was first isolated from Tabernanthe iboga root bark in 1901.citation needed The Bwiti people of Gabon and Cameroon had used the bark in initiation ceremonies for centuries before its isolation.[7][8] Its anti-addictive potential was discovered in 1962 when Howard Lotsof took it and found his heroin cravings had vanished; he patented the application in 1985.[9]
Clinical significance
US federal research ran from 1991 to 1995 and the FDA authorized an experimental drug application in 1993, but NIDA ended the program after high-dose rat studies raised concerns about brain damage. Deborah Mash continued open-label work at Caribbean clinics, publishing the largest prospective clinical series in 2018.[10]
Prohibition and modern use
Ibogaine was classified Schedule I in the US around 1967, formalized under the Controlled Substances Act of 1970. New Zealand made it available by prescription in 2009. A 2024 Stanford trial in Nature Medicine demonstrated large benefits for veterans with PTSD,[4] Texas allocated $50 million for FDA clinical research, and a 2026 executive order has accelerated regulatory review and patient access.[9][11]
The name ibogaine derives from iboga, from the Fang and Mitsogho languages of Gabon. In Bwiti tradition the root bark is consumed during initiation as a sacrament — contact with ancestors and the spirit world, not therapy.
Chemistry[edit]
Structural class
Ibogaine belongs to the iboga alkaloid family — a class of compounds built on an indole ring fused to a complex bridged ring system, structurally distinct from tryptamine and phenethylamine psychedelics. Its molecular formula is C₂₀H₂₆N₂O (molecular weight 310.4 g/mol).
Most commercial ibogaine is produced by semi-synthesis from voacangine, an alkaloid found in Voacanga africana at much higher concentrations than in T. iboga itself.[13]
Pharmacology[edit]
Mechanism of action
Ibogaine acts on several addiction-relevant brain systems at once: it activates kappa-opioid receptors,[1] blocks glutamate signaling,[2] inhibits serotonin reuptake, and blocks nicotinic acetylcholine receptors.[3] No single mechanism explains the full anti-addictive effect — the convergence of all of them does.[14]
A key downstream effect is the release of GDNF — a growth factor that supports long-term repair of dopamine neurons — in the brain's reward circuit.[15] Noribogaine, ibogaine's main metabolite, also triggers GDNF release, extending this effect for days after a single dose.[16]
Pharmacokinetics
The liver enzyme CYP2D6 converts ibogaine to noribogaine, which lasts far longer in the body — 28–49 hours versus ibogaine's 1–10 hours[17] — sustaining both therapeutic activity and cardiac risk. People with reduced CYP2D6 activity, whether genetic or caused by certain antidepressants, accumulate roughly twice the drug exposure[18] and face elevated cardiac risk.[18]
Neuroscience[edit]
Where it acts
In the brain's reward center, ibogaine suppresses dopamine activity — opposing the surges that drugs of abuse produce.[19][20] In the area that drives motivation, ibogaine and its metabolite noribogaine trigger the release of GDNF, a growth factor that supports long-term repair of dopamine neurons.[15][16]
Why it matters
The leading theory is that ibogaine reopens a critical period for reward learning — restoring the brain's capacity to form new associations after addiction has made circuits pathologically rigid.[21] Rather than blocking a specific drug receptor, this model holds that ibogaine resets the brain's ability to relearn reward patterns through GDNF-driven structural change.
- Does cerebellar damage occur in humans? In rats, large injected doses cause selective death of cerebellar cells,[22] but typical human doses are well below that threshold.[23] No brain imaging studies have examined this in people.[24]
- What sustains the anti-addictive effect? Benefits often last weeks to months — far beyond noribogaine's clearance. GDNF-mediated brain remodeling is the leading hypothesis, but direct human evidence is lacking.
- Can the effect work without the visionary experience? The derivative 18-MC retains some anti-addictive efficacy without psychoactivity but lacks GDNF induction, leaving the question unresolved.
Subjective Effects[edit]
Ibogaine generates an experience that turns inward rather than distorting external perception. It takes the form of a waking dream — a lucid, narrative review of personal memories watched from a detached observer perspective.[25] Physical surroundings recede completely, and the content is shaped by psychological preparation and intention more than by the immediate environment.[26][27]
Among commonly known psychedelics, ibogaine has no close parallel. Where psilocybin and LSD amplify incoming perception, ibogaine replaces it with an entirely internally generated cinema. The physical burden is also far heavier than any classical psychedelic — severe loss of coordination and persistent nausea accompany the experience throughout.
Effect Grid
At common doses (10–20 mg/kg oral), the full ibogaine experience emerges. The dominant feature is an oneiric waking-dream state: vivid, panoramic autobiographical imagery — "life review" scenes from personal history arising with eyes open or closed. This is qualitatively distinct from geometric or entity-contact hallucinations of serotonergic psychedelics. Intense introspection, emotional catharsis, and existential insight characterize the cognitive dimension. Time distortion is profound.
Physically, severe ataxia renders standing and walking impossible; patients must remain supine throughout. Nausea and vomiting are common during onset. Bradycardia is consistent and dose-dependent. Sleep is suppressed for 24–36 hours.
This is the addiction-treatment dose range used in clinical settings. The experience demands 36–48 hours of committed time and medical monitoring. QTc prolongation risk is clinically significant.
Modeled from the effect's dose-dependence curve — not per-substance measurements.
Spatial disorientation · Light sensitivity · Proprioceptive distortion · Vestibular distortion · Perspective distortion · Color alteration · Auditory distortion · Brightness alteration · Sound sensitivity · Tinnitus · Visual drifting · Auditory misinterpretation · Depth perception distortion · Visual haze / noise · Visual morphing · Color enhancement · Tracers · After-images · Geometry · Peripheral vision distortion · Visual acuity suppression · Visual breathing · Touch suppression · Music enhancement · Visual melting · Synesthesia · Symmetrical texture repetition · Flashbacks · Visual acuity enhancement · Internal hallucinations · Visual processing suppression · Auditory hallucinations · External hallucinations · Object transformations · Perspective hallucinations
Perspective distortion · Color alteration · Auditory distortion · Brightness alteration · Sound sensitivity · Tinnitus · Visual drifting · Auditory misinterpretation · Depth perception distortion · Visual haze / noise · Visual morphing · Color enhancement · Tracers · After-images · Geometry · Peripheral vision distortion · Visual acuity suppression · Visual breathing · Touch suppression · Music enhancement · Visual melting · Synesthesia · Symmetrical texture repetition · Flashbacks · Visual acuity enhancement · Internal hallucinations · Visual processing suppression · Auditory hallucinations · External hallucinations · Object transformations · Perspective hallucinations
Insomnia · Nystagmus (eye wobbles) · Physical fatigue · Sedation · Pupil dilation · Spontaneous body sensations · Involuntary body movements · Appetite suppression · Bodily heaviness · Heart rate perception changes · Trembling · Vomiting · Abnormal heartbeat · Muscle tension · Body schema distortion · Excessive sweating · Tingling / electric sensations · Stimulation · Dehydration sensation · Breathing alteration · Headache · Restlessness · Vibrations / buzzing · Constipation · Pain suppression · Salivation · Diarrhea · Sexual arousal enhancement · Bodily dissociation
Sedation · Pupil dilation · Spontaneous body sensations · Involuntary body movements · Appetite suppression · Bodily heaviness · Heart rate perception changes · Trembling · Vomiting · Muscle tension · Body schema distortion · Excessive sweating · Tingling / electric sensations · Stimulation · Dehydration sensation · Breathing alteration · Headache · Restlessness · Vibrations / buzzing · Constipation · Pain suppression · Salivation · Diarrhea · Sexual arousal enhancement · Bodily dissociation
Immersion enhancement · Cognitive fatigue · Confusion · Thought disorganization · Novelty enhancement · Focus suppression · Information processing suppression · Openness enhancement · Memory enhancement · Thought loops · Pattern recognition enhancement · Conceptual thinking · Cognitive dysphoria · Multiple thought streams · Thought connectivity · Cognitive flexibility · Memory fragmentation · Analysis enhancement · Motivation enhancement · Increased nature relatedness · Synchronicity · Creativity enhancement · Thought organization · Delusions · Delirium · Amnesia
Thought disorganization · Novelty enhancement · Focus suppression · Information processing suppression · Openness enhancement · Memory enhancement · Thought loops · Pattern recognition enhancement · Conceptual thinking · Cognitive dysphoria · Multiple thought streams · Thought connectivity · Cognitive flexibility · Memory fragmentation · Analysis enhancement · Motivation enhancement · Increased nature relatedness · Synchronicity · Creativity enhancement · Thought organization · Delirium · Amnesia
Anxiety · Simultaneous emotions · Dysphoria · Empathy enhancement · Irritability · Euphoria
Irritability · Euphoria
Derealization · Emotional susceptibility · Social disconnection · Self-control enhancement · Social connection · Trust enhancement · Identity alteration · Cognitive disconnection · Boundary dissolution · Ego dissolution
Social connection · Trust enhancement · Identity alteration · Cognitive disconnection · Boundary dissolution · Ego dissolution
Transpersonal visions · Entity contact · Transpersonal feelings · Near-death experience · Non-dual awareness · Voidness · Cessation
Non-dual awareness · Voidness · Cessation
Lucidity enhancement · Recursive awareness
Timeline
First effects emerge as mild nausea, slight perceptual brightening, and building bodily awareness. The wide onset range (30 minutes to 3 hours) reflects variable oral absorption and CYP2D6 metabolizer status.
Nausea intensifies. Ataxia develops rapidly, requiring the supine position. Early visual disturbances and internal imagery begin.
The full oneiric waking-dream state dominates: vivid panoramic autobiographical imagery, life review scenes, and deep introspective engagement. Severe ataxia, bradycardia, and tremor persist. Sleep is impossible.
Oneiric imagery gradually fades, replaced by sustained introspection and emotional processing. Physical symptoms begin to ease but ataxia and nausea may persist. Wakefulness continues.
Cognitive clarity slowly returns. Motor coordination improves but remains impaired. Residual visual phenomena and emotional sensitivity persist.
A prolonged afterglow lasting 1–3 days features emotional openness, reflective mood, mild cognitive changes, and continued integration of the experience. Noribogaine remains pharmacologically active (t1/2 28–49 hours), sustaining subtle effects and maintaining cardiac risk.
⚠ Do not drive or operate heavy machinery for at least 72 hours after ibogaine ingestion; impairment from noribogaine persists well beyond subjective resolution.
Safety[edit]
- Acute toxicity
- High
- Chronic toxicity
- Low
- Withdrawal
- None
- Tolerance buildup
- none
- Tolerance reset
- —
- Physical
- None
- Psychological
- Negligible
- Compulsive redosing
- Negligible
- Dose escalation
- Negligible
- Cross-tol.
- —
Toxicity
Cardiac risk (primary)
Ibogaine and noribogaine both block the hERG channel at concentrations reached during therapeutic use.[6][28] Multiple deaths have been documented, most attributed to a fatal rhythm called torsades de pointes progressing to cardiac arrest.[29][30] Noribogaine's long half-life means the cardiac danger window extends days after ibogaine itself has cleared.[28][29]
The Stanford MISTIC protocol used magnesium as cardiac protection; no unexpected serious adverse events occurred in 30 participants.[4] Reversible QT prolongation was documented in a Dutch opioid detox study,[7] noribogaine alone produces dose-dependent QT prolongation,[31] and arrhythmia has followed unregulated internet-purchased ibogaine.[32]
Cerebellar neurotoxicity
In rats, very high injected doses cause selective death of cerebellar nerve cells.[22] Human therapeutic doses are substantially below that threshold,[23] and no human neuroimaging studies have examined whether this occurs in people.[24]
Acute physical effects
Severe loss of coordination makes walking impossible during the acute phase — patients must remain lying down.[7] Nausea and vomiting are common at onset. Heart rate slows dose-dependently,[20] and sleep is suppressed for 24–36 hours.
Psychological Risks
Published clinical studies have not reported persistent psychosis or lasting perceptual disturbances after ibogaine. The experience can involve intense emotional content including traumatic memories, and psychological distress during the session is expected. No controlled data on adverse psychological outcomes exist — available evidence comes from screened observational series.
Tolerance & Dependence
Ibogaine does not support self-administration in animal models,[5] and no human cases of ibogaine dependence or compulsive redosing have been reported. The standard clinical model — single or widely-spaced doses — means tolerance cannot be meaningfully assessed from existing data.
Drug Interactions
CYP2D6 inhibitors (high risk)
Common antidepressants including paroxetine, fluoxetine, bupropion, and duloxetine block CYP2D6, the liver enzyme that breaks down ibogaine. Paroxetine roughly doubles ibogaine exposure in the bloodstream,[18] concentrating both cardiac and psychedelic risk. People with genetically low CYP2D6 activity face the same elevated exposure without taking any inhibitor.[18]
QT-prolonging medications (high risk)
Many medications stretch the heart's electrical recharge time — the same mechanism as ibogaine. Combining them creates additive risk that can be lethal. These include certain antipsychotics (haloperidol, ziprasidone), heart rhythm medications (quinidine, sotalol, amiodarone), antibiotics (azithromycin, fluoroquinolones), methadone, and tricyclic antidepressants.
Opioids (high risk)
During ibogaine treatment, patients cannot walk or protect their airway. If opioids are present and breathing slows, the inability to move becomes life-threatening. One early fatality was attributed to covert heroin use during ibogaine treatment.[12] A complete opioid washout is required before any session.
Serotonergic drugs
Ibogaine blocks serotonin reuptake. Adding SSRIs, MAOIs, or serotonin-releasing agents on top of that can trigger dangerous serotonin overload — overheating, rapid heart rate, and seizures. No published cases of this combination exist, but concurrent serotonergic medication should be stopped before treatment.
P-glycoprotein inhibitors
Drugs that inhibit the P-glycoprotein transporter (verapamil, cyclosporine) may increase how much ibogaine reaches the brain.[33] Clinical significance has not been characterized.
Contraindications
Absolute
- Pre-existing QT prolongation — baseline QTc >450 ms (men) or >470 ms (women)[29][30]
- Irregular heartbeat or structural heart disease[29][30]
- Concurrent QT-prolonging medication
- Concurrent opioid use — requires complete washout[12]
Relative
- Severe liver impairment — impaired metabolism may unpredictably alter drug exposure
- Low potassium or magnesium — correct before treatment[7][25]
- CYP2D6 inhibitor use without dose adjustment[18]
- Pregnancy — no safety data existsafety citation needed
Harm Reduction[edit]
Forms & Identification
Ibogaine circulates as hydrochloride salt powder or capsules, sourced from T. iboga root bark extraction or semi-synthesis from voacangine. Total alkaloid extracts (TA) contain ibogaine alongside other iboga alkaloids at variable ratios — precise dosing is unreliable. Purified ibogaine HCl is the preferred clinical form.
Reagent testing alone cannot establish safety. The margin between therapeutic and cardiotoxic exposure is too narrow to trust unverified material — quantitative purity analysis is essential for any preparation. If using a total alkaloid extract, the ibogaine content is uncertain and the effective dose cannot be reliably calculated.
Guidelines
- Obtain a baseline ECG and cardiac clearance before any ibogaine session
- Complete CYP2D6 genotyping if available — poor metabolizers require significant dose reduction
- Discontinue all QT-prolonging medications, opioids, SSRIs, and CYP2D6 inhibitors with appropriate washout periods
- Correct any electrolyte imbalances (potassium, magnesium) before treatment
- Fast for 8–12 hours before ingestion to reduce nausea
- Ensure continuous cardiac monitoring (at minimum pulse oximetry and heart rate) for the first 24 hours, ideally 48 hours
- Have at least one experienced sitter present for the full duration — plan for 36+ hours of supervision
- Keep the space quiet, dimly lit, and free from interruption
- Provide water and electrolytes for the recovery phase
- Do not attempt to stand or walk during the acute phase — severe loss of coordination makes falls a serious risk
Set & Setting
The severe physical impairment of the acute phase makes setting fundamentally different from shorter-acting psychedelics. Patients cannot walk — lying down is mandatory. A private, quiet space with a bed is essential, and continuous monitoring by an experienced sitter or medical professional is the minimum safety requirement given the cardiac risk window.
Therapeutic intention and psychological preparation substantially shape the oneiric content. Pre-session work with a therapist — clarifying intentions, reviewing personal history — improves both experience quality and outcomes. The visionary state will surface autobiographical material including potentially traumatic memories, and psychological readiness for this content is critical.
Aftercare & integration. The 24–72 hours following the acute phase are a period of continued psychological processing. Sleep will return gradually — do not force it. Light meals, hydration, and quiet company support physical recovery.
The oneiric experience often surfaces deeply personal material that benefits from structured reflection. Journaling, conversation with a trusted person, or sessions with an integration therapist help consolidate insights.
Many clinical programs schedule integration sessions in the days and weeks following treatment. If disturbing material arose during the experience, professional support is especially valuable — do not process traumatic content alone.
Recovery & Support
Ibogaine is an intervention, not a cure. The window of reduced craving that follows — often lasting weeks to months — is an opportunity to establish new patterns. Aftercare programs, peer support, and ongoing therapy substantially improve long-term outcomes.
For those using ibogaine in the context of opioid dependence, connection with addiction medicine specialists and recovery communities before treatment ensures continuity of care. Organizations such as the Global Ibogaine Therapy Alliance provide information and referrals.
Recovery resources, crisis lines, and support pathways → View all
Emergency Response
Recognizing an emergency: Ibogaine's physical effects — nausea, inability to walk, slowed heart rate — are expected and do not alone indicate crisis. Seek immediate medical help for: chest pain or pressure, fainting or loss of consciousness, seizure, heart rate below 40 bpm or irregular rhythm, breathing difficulty, or unresponsiveness.
Immediate steps:
- 1. Call emergency services immediately if any red flag is present
- 2. Place the person on their side (recovery position) to protect the airway
- 3. Do not leave them alone
- 4. Do not induce vomiting
- 5. Monitor breathing and heart rate continuously while waiting for help
What to tell the dispatcher: Report that the person has taken ibogaine, the approximate dose and time of ingestion, and current symptoms — especially any cardiac symptoms. Good Samaritan laws in many jurisdictions protect people who call for help during a drug-related emergency.
Legal Status[edit]
Ibogaine is federally prohibited in the United States and several European countries, available by physician prescription in New Zealand, and unregulated or accessible through treatment centers in a handful of other jurisdictions.
| Jurisdiction | Classification | Key provisions |
|---|---|---|
| United States | Schedule I (Controlled Substances Act, 1970) | Federally prohibited since ~1967; no accepted medical use under current scheduling. Texas allocated $50M for FDA clinical research (2025); 2026 executive order accelerating research and Right to Try access[9][11] |
| New Zealand | Non-approved medicine (prescription) | Available by physician prescription since 2009; case-by-case justification and clinical supervision required |
| Canada | Prescription Drug (Food and Drug Regulations) | Theoretically accessible via Special Access Program; approvals rare in practice |
| United Kingdom | Prohibited (Psychoactive Substances Act 2016) | Blanket prohibition; no medical exemptions |
| France | Prohibited | No medical exemptions |
| Belgium | Prohibited | No medical exemptions |
| Sweden | Prohibited | No medical exemptions |
| Switzerland | Prohibited | No medical exemptions |
| Portugal | Decriminalized (personal possession since 2001) | Commercial treatment operations remain illegal |
| Mexico | Unregulated | Treatment centers operate in legal gray area; not explicitly prohibited or formally approved |
| Costa Rica | Unregulated | No legal restrictions[34] |
| The Bahamas | Permitted for clinical use | Established treatment centers with US-standard medical protocols |
| Australia | Regulated (TGA oversight) | Not explicitly scheduled on SUSMP but regulated as prescription-only; effectively not clinically available |
references
- [1] ^abDeecher DC, Teitler M, Soderlund DM, Bornmann WG, Kuehne ME, Glick SD (1992) Mechanisms of action of ibogaine and harmaline congeners based on radioligand binding studies — Brain research PMID:1377086
- [2] ^abChen K, Kokate TG, Donevan SD, Carroll FI, Rogawski MA (1996) Ibogaine block of the NMDA receptor: in vitro and in vivo studies — Neuropharmacology PMID:8793904
- [3] ^abSweetnam PM, Lancaster J, Snowman A, Collins JL, Perschke S, Bauer C, Ferkany J (1995) Receptor binding profile suggests multiple mechanisms of action are responsible for ibogaine's putative anti-addictive activity — Psychopharmacology PMID:7568622
- [4] ^abcCherian KN, Keynan JN, Anker L, et al. (2024) Magnesium-ibogaine therapy in veterans with traumatic brain injuries — Nature medicine doi:10.1038/s41591-023-02705-w
- [5] ^abBelgers M, Leenaars M, Homberg JR, Ritskes-Hoitinga M, Schellekens AF, Hooijmans CR (2016) Ibogaine and addiction in the animal model, a systematic review and meta-analysis — Translational psychiatry doi:10.1038/tp.2016.71
- [6] ^abAlper K, Bai R, Liu N, Fowler SJ, Huang XP, Priori SG, Ruan Y (2016) hERG Blockade by Iboga Alkaloids — Cardiovascular toxicology doi:10.1007/s12012-015-9311-5